Roche's Gazyva® Short-Duration Infusion Protocol Approved in China

36Kr learned that, according to the official WeChat account of Roche Pharmaceuticals, the short-duration infusion (SDI) regimen of Gazyva® (Obinutuzumab) can significantly reduce the administration time for patients with hematologic malignancies from approximately 4 hours under the standard regimen to just 90 minutes. This brings multi-dimensional benefits, including enhanced treatment convenience, improved patient quality of life, saved medical staff time, and alleviated pressure on infusion facilities. The GAZELEE study demonstrated that the Obinutuzumab SDI regimen is well-tolerated and has equivalent efficacy to the standard regimen.Original link